The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions

Objective:There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and int...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of neuropsychiatry and clinical neurosciences 2021-01, Vol.33 (1), p.72-79
Hauptverfasser: Minen, Mia T, Gopal, Ariana, Sahyoun, Gabriella, Stieglitz, Eric, Torous, John
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 79
container_issue 1
container_start_page 72
container_title The journal of neuropsychiatry and clinical neurosciences
container_volume 33
creator Minen, Mia T
Gopal, Ariana
Sahyoun, Gabriella
Stieglitz, Eric
Torous, John
description Objective:There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.Methods:This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer’s disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were
doi_str_mv 10.1176/appi.neuropsych.19120353
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8670295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2424442310</sourcerecordid><originalsourceid>FETCH-LOGICAL-a466t-9bac44ebf3b082074a8f589964885cd03fcc02cb1ffc07ead592bbc94cae991a3</originalsourceid><addsrcrecordid>eNqFkUFv2yAYhtHUaU27_YWJYw919oHBNpdKUdR2lapt0rIzwhgvVA5QsCPl35csbdqedkKC93u-Fz0IYQJzQurqmwrBzp2Zog9pp9dzIgiFkpcf0IxwxouaUnqCZtAIXgCp6Sk6S-kBAGhZsU_otKRVJYDCDLnV2uCbyenReqcGO-4u8fXWdsZpc4mV6_CvaLdK7_BdSpNJeBH9lG9_b1Qcw9o7gxchJNz7iMeMWvmAfxyLWTVGq_HSu87uF6TP6GOvhmS-PJ_n6M_N9Wr5vbj_eXu3XNwXilXVWIhWacZM25ctNBRqppqeN0JUrGm47qDstQaqW9L3GmqjOi5o22rBtDJCEFWeo6sDN0ztxnTauDGqQYZoc--d9MrK9y_OruVfv5VNVQMVPAMungHRP-Z_j3JjkzbDoJzxU5KUUcYYLQnkaHOI6uhTiqY_riEg97rkXpd81SVfdOXRr29rHgdf_OQAPwT-IR78FLOk9H_wE4eUrAc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424442310</pqid></control><display><type>article</type><title>The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions</title><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Minen, Mia T ; Gopal, Ariana ; Sahyoun, Gabriella ; Stieglitz, Eric ; Torous, John</creator><creatorcontrib>Minen, Mia T ; Gopal, Ariana ; Sahyoun, Gabriella ; Stieglitz, Eric ; Torous, John</creatorcontrib><description>Objective:There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.Methods:This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer’s disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were &lt;$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment.Results:Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer’s disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes.Conclusions:Most apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.</description><identifier>ISSN: 0895-0172</identifier><identifier>EISSN: 1545-7222</identifier><identifier>DOI: 10.1176/appi.neuropsych.19120353</identifier><identifier>PMID: 32669020</identifier><language>eng</language><publisher>United States: American Psychiatric Association</publisher><subject>Alzheimer Disease - therapy ; Cross-Sectional Studies ; Depression - therapy ; Evidence-Based Practice - standards ; Humans ; Migraine Disorders - therapy ; Mobile Applications ; Privacy ; Smartphone - instrumentation ; Stroke - therapy</subject><ispartof>The journal of neuropsychiatry and clinical neurosciences, 2021-01, Vol.33 (1), p.72-79</ispartof><rights>Copyright © 2020 by the American Psychiatric Association 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a466t-9bac44ebf3b082074a8f589964885cd03fcc02cb1ffc07ead592bbc94cae991a3</citedby><cites>FETCH-LOGICAL-a466t-9bac44ebf3b082074a8f589964885cd03fcc02cb1ffc07ead592bbc94cae991a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.neuropsych.19120353$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.neuropsych.19120353$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>230,314,780,784,885,2855,21626,21627,21628,27924,27925,77794,77799</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32669020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minen, Mia T</creatorcontrib><creatorcontrib>Gopal, Ariana</creatorcontrib><creatorcontrib>Sahyoun, Gabriella</creatorcontrib><creatorcontrib>Stieglitz, Eric</creatorcontrib><creatorcontrib>Torous, John</creatorcontrib><title>The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions</title><title>The journal of neuropsychiatry and clinical neurosciences</title><addtitle>J Neuropsychiatry Clin Neurosci</addtitle><description>Objective:There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.Methods:This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer’s disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were &lt;$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment.Results:Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer’s disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes.Conclusions:Most apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.</description><subject>Alzheimer Disease - therapy</subject><subject>Cross-Sectional Studies</subject><subject>Depression - therapy</subject><subject>Evidence-Based Practice - standards</subject><subject>Humans</subject><subject>Migraine Disorders - therapy</subject><subject>Mobile Applications</subject><subject>Privacy</subject><subject>Smartphone - instrumentation</subject><subject>Stroke - therapy</subject><issn>0895-0172</issn><issn>1545-7222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFv2yAYhtHUaU27_YWJYw919oHBNpdKUdR2lapt0rIzwhgvVA5QsCPl35csbdqedkKC93u-Fz0IYQJzQurqmwrBzp2Zog9pp9dzIgiFkpcf0IxwxouaUnqCZtAIXgCp6Sk6S-kBAGhZsU_otKRVJYDCDLnV2uCbyenReqcGO-4u8fXWdsZpc4mV6_CvaLdK7_BdSpNJeBH9lG9_b1Qcw9o7gxchJNz7iMeMWvmAfxyLWTVGq_HSu87uF6TP6GOvhmS-PJ_n6M_N9Wr5vbj_eXu3XNwXilXVWIhWacZM25ctNBRqppqeN0JUrGm47qDstQaqW9L3GmqjOi5o22rBtDJCEFWeo6sDN0ztxnTauDGqQYZoc--d9MrK9y_OruVfv5VNVQMVPAMungHRP-Z_j3JjkzbDoJzxU5KUUcYYLQnkaHOI6uhTiqY_riEg97rkXpd81SVfdOXRr29rHgdf_OQAPwT-IR78FLOk9H_wE4eUrAc</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Minen, Mia T</creator><creator>Gopal, Ariana</creator><creator>Sahyoun, Gabriella</creator><creator>Stieglitz, Eric</creator><creator>Torous, John</creator><general>American Psychiatric Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions</title><author>Minen, Mia T ; Gopal, Ariana ; Sahyoun, Gabriella ; Stieglitz, Eric ; Torous, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a466t-9bac44ebf3b082074a8f589964885cd03fcc02cb1ffc07ead592bbc94cae991a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer Disease - therapy</topic><topic>Cross-Sectional Studies</topic><topic>Depression - therapy</topic><topic>Evidence-Based Practice - standards</topic><topic>Humans</topic><topic>Migraine Disorders - therapy</topic><topic>Mobile Applications</topic><topic>Privacy</topic><topic>Smartphone - instrumentation</topic><topic>Stroke - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minen, Mia T</creatorcontrib><creatorcontrib>Gopal, Ariana</creatorcontrib><creatorcontrib>Sahyoun, Gabriella</creatorcontrib><creatorcontrib>Stieglitz, Eric</creatorcontrib><creatorcontrib>Torous, John</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of neuropsychiatry and clinical neurosciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minen, Mia T</au><au>Gopal, Ariana</au><au>Sahyoun, Gabriella</au><au>Stieglitz, Eric</au><au>Torous, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions</atitle><jtitle>The journal of neuropsychiatry and clinical neurosciences</jtitle><addtitle>J Neuropsychiatry Clin Neurosci</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>33</volume><issue>1</issue><spage>72</spage><epage>79</epage><pages>72-79</pages><issn>0895-0172</issn><eissn>1545-7222</eissn><abstract>Objective:There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies.Methods:This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer’s disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were &lt;$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment.Results:Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer’s disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes.Conclusions:Most apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.</abstract><cop>United States</cop><pub>American Psychiatric Association</pub><pmid>32669020</pmid><doi>10.1176/appi.neuropsych.19120353</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0895-0172
ispartof The journal of neuropsychiatry and clinical neurosciences, 2021-01, Vol.33 (1), p.72-79
issn 0895-0172
1545-7222
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8670295
source MEDLINE; American Psychiatric Publishing Journals (1997-Present); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Alzheimer Disease - therapy
Cross-Sectional Studies
Depression - therapy
Evidence-Based Practice - standards
Humans
Migraine Disorders - therapy
Mobile Applications
Privacy
Smartphone - instrumentation
Stroke - therapy
title The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A54%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Functionality,%20Evidence,%20and%20Privacy%20Issues%20Around%20Smartphone%20Apps%20for%20the%20Top%20Neuropsychiatric%20Conditions&rft.jtitle=The%20journal%20of%20neuropsychiatry%20and%20clinical%20neurosciences&rft.au=Minen,%20Mia%20T&rft.date=2021-01-01&rft.volume=33&rft.issue=1&rft.spage=72&rft.epage=79&rft.pages=72-79&rft.issn=0895-0172&rft.eissn=1545-7222&rft_id=info:doi/10.1176/appi.neuropsych.19120353&rft_dat=%3Cproquest_pubme%3E2424442310%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2424442310&rft_id=info:pmid/32669020&rfr_iscdi=true